NASDAQ: IKTInhibikase Therapeutics Inc Stock
$1.90-0.08 (-4.04%)
Updated Apr 17, 2025
IKT Price
$1.90
Fair Value Price
$2.38
Market Cap
$141.25M
52 Week Low
$1.12
52 Week High
$4.20
P/E
-1.64x
P/B
1.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$27.52M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$19M
Beta
0.86
Next Earnings
Jun 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IKT Overview
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IKT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IKT
Ranked#140 of 463
Ranked#140 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important IKT news, forecast changes, insider trades & much more!
IKT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IKT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IKT ($1.90) is undervalued by 20.09% relative to our estimate of its Fair Value price of $2.38 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IKT ($1.90) is significantly undervalued by 20.09% relative to our estimate of its Fair Value price of $2.38 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IKT due diligence checks available for Premium users.
Valuation
IKT fair value
Fair Value of IKT stock based on Discounted Cash Flow (DCF)
Price
$1.90
Fair Value
$2.38
Undervalued by
20.09%
IKT ($1.90) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IKT ($1.90) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IKT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.64x
Industry
-177.72x
Market
27.98x
IKT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.49x
Industry
4.05x
IKT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IKT's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.1M
Profit Margin
0%
IKT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$98.6M
Liabilities
$3.7M
Debt to equity
0.04
IKT's short-term assets ($98.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IKT's short-term assets ($98.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IKT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IKT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.3M
Investing
-$38.8M
Financing
$99.7M
IKT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IKT vs Biotech Stocks
Inhibikase Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.